# Editorial: Use of radiation therapy for hematological malignancies

**Authors:** Carla Hajj, Dana L. Casey, Brandon S. Imber

PMC · DOI: 10.3389/fonc.2026.1781001 · Frontiers in Oncology · 2026-02-20

## Full-text entities

- **Genes:** KRT20 (keratin 20) [NCBI Gene 54474] {aka CD20, CK-20, CK20, K20, KRT21}, ATM (ATM serine/threonine kinase) [NCBI Gene 472] {aka AT1, ATA, ATC, ATD, ATDC, ATE}, CD19 (CD19 molecule) [NCBI Gene 930] {aka B4, CVID3}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}
- **Diseases:** skin toxicity (MESH:D012871), leukemia (MESH:D007938), toxicity (MESH:D064420), graft versus host disease (MESH:D006086), myeloma (MESH:D009101), neurotoxicity (MESH:D020258), cancers (MESH:D009369), pneumonitis (MESH:D011014), non-Hodgkin lymphoma (MESH:D008228), Primary cutaneous lymphomas (MESH:D008223), B cell lymphomas (MESH:D016393), nausea (MESH:D009325), cranial neuropathies (MESH:D003389), neurologic deficits (MESH:D009461), diffuse large B cell lymphoma (MESH:D016403), hematologic malignancies (MESH:D019337)
- **Chemicals:** rituximab (MESH:D000069283)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12962999/full.md

---
Source: https://tomesphere.com/paper/PMC12962999